A Phase 1 Study of S-3304 in Patients With Solid Tumors
Status:
Completed
Trial end date:
2003-03-12
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy
accessible cancer who have failed previous therapy or to whom no standard therapies are
available. To determine the pharmacokinetic profile of S-3304 in this patient population